ECSP14023407A - Virus de la enfermedad de marek modificado y vacunas elaboradas con él - Google Patents

Virus de la enfermedad de marek modificado y vacunas elaboradas con él

Info

Publication number
ECSP14023407A
ECSP14023407A ECIEPI201423407A ECPI201423407A ECSP14023407A EC SP14023407 A ECSP14023407 A EC SP14023407A EC IEPI201423407 A ECIEPI201423407 A EC IEPI201423407A EC PI201423407 A ECPI201423407 A EC PI201423407A EC SP14023407 A ECSP14023407 A EC SP14023407A
Authority
EC
Ecuador
Prior art keywords
marek
disease virus
disease
mdv
vaccine
Prior art date
Application number
ECIEPI201423407A
Other languages
English (en)
Inventor
Joyce Pritchard
Teshome Mebatsion
Michel Bublot
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of ECSP14023407A publication Critical patent/ECSP14023407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vacuna eficaz para combatir la enfermedad de Marek, que puede elaborarse usando un virus de la enfermedad de Marek (MDV) recombinante de la cepa CVI988, que ha sido transformado con una construcción de ADN exógeno que comprende la secuencia de la repetición terminal larga de un virus de la reticuloendoteliosis. Este agente viral seguro es útil para generar una respuesta inmune de protección importante ante un ataque con un MDV virulento en un pollo, aunque no se caracteriza por una patogenicidad significativa. Las formulaciones apropiadas de esta vacuna que puede usarse en pollos comprenden dosis de este agente viral novedoso que son eficaces para la inmunización, junto con vehículos o diluyentes farmacéuticamente aceptables.
ECIEPI201423407A 2012-03-22 2014-10-17 Virus de la enfermedad de marek modificado y vacunas elaboradas con él ECSP14023407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261614142P 2012-03-22 2012-03-22
PCT/US2013/032539 WO2013142377A2 (en) 2012-03-22 2013-03-15 Modified marek's disease virus, and vaccines made therefrom

Publications (1)

Publication Number Publication Date
ECSP14023407A true ECSP14023407A (es) 2015-06-30

Family

ID=48045766

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201423407A ECSP14023407A (es) 2012-03-22 2014-10-17 Virus de la enfermedad de marek modificado y vacunas elaboradas con él

Country Status (28)

Country Link
US (3) US20130251737A1 (es)
EP (2) EP3326646A1 (es)
JP (1) JP2015512396A (es)
KR (5) KR102586316B1 (es)
CN (1) CN104602706A (es)
AP (1) AP2014007955A0 (es)
AR (1) AR090472A1 (es)
BR (1) BR112014023398A8 (es)
CA (1) CA2868099C (es)
CR (1) CR20140432A (es)
DO (1) DOP2014000215A (es)
EA (1) EA030866B1 (es)
EC (1) ECSP14023407A (es)
ES (1) ES2663610T3 (es)
GE (1) GEP201706650B (es)
GT (1) GT201400199A (es)
HK (1) HK1255682A1 (es)
IL (1) IL234721B (es)
MA (1) MA37432A1 (es)
MX (1) MX355332B (es)
MY (1) MY169061A (es)
NL (1) NL301087I2 (es)
PE (1) PE20150323A1 (es)
PH (1) PH12014502085A1 (es)
TN (1) TN2014000393A1 (es)
UA (1) UA117345C2 (es)
WO (1) WO2013142377A2 (es)
ZA (1) ZA201406884B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868099C (en) * 2012-03-22 2020-12-15 Merial Limited Modified marek's disease virus, and vaccines made therefrom
CN106397602B (zh) * 2016-08-02 2019-06-18 青岛明勤生物科技有限公司 一种分子佐剂加强型鸡马立克氏病蛋白工程疫苗
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642574A (en) 1970-04-29 1972-02-15 Us Agriculture Method for producing vaccine for immunization of poultry against marek{3 s disease
US4160024A (en) 1978-05-01 1979-07-03 Cornell Research Foundation, Inc. Marek's disease vaccine
NL8401120A (nl) 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US4895718A (en) 1987-07-10 1990-01-23 The United States Of America, As Represented By The Secretary Of Agriculture Serotype 2 Marek's disease vaccine
US4895717A (en) 1987-07-10 1990-01-23 The United States Of America As Represented By The Secretary Of Agriculture Revertant serotype 1 Marek's disease vaccine
CN1261807A (zh) 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向横纹肌中转移核酸的改进方法和用于实施该方法的组合
US20050019348A1 (en) 2003-07-21 2005-01-27 Reddy Sanjay M. Marek's disease virus vaccine
CA2868099C (en) * 2012-03-22 2020-12-15 Merial Limited Modified marek's disease virus, and vaccines made therefrom
US9113301B1 (en) 2014-06-13 2015-08-18 Snapchat, Inc. Geo-location based event gallery

Also Published As

Publication number Publication date
MX355332B (es) 2018-04-16
UA117345C2 (uk) 2018-07-25
EA201401044A1 (ru) 2015-01-30
DOP2014000215A (es) 2015-04-15
KR20190100431A (ko) 2019-08-28
KR102586316B1 (ko) 2023-10-06
PE20150323A1 (es) 2015-03-05
HK1255682A1 (en) 2019-08-23
BR112014023398A8 (pt) 2022-08-16
MX2014011388A (es) 2014-10-14
KR20140146136A (ko) 2014-12-24
US11510978B2 (en) 2022-11-29
EP3326646A1 (en) 2018-05-30
US20230310589A1 (en) 2023-10-05
EP2827898A2 (en) 2015-01-28
KR20230028595A (ko) 2023-02-28
CA2868099C (en) 2020-12-15
MA37432A1 (fr) 2016-03-31
AP2014007955A0 (en) 2014-09-30
CA2868099A1 (en) 2013-09-26
US20130251737A1 (en) 2013-09-26
JP2015512396A (ja) 2015-04-27
ES2663610T3 (es) 2018-04-16
NL301087I2 (nl) 2022-03-11
KR20230145532A (ko) 2023-10-17
IL234721B (en) 2018-05-31
MY169061A (en) 2019-02-12
ZA201406884B (en) 2015-11-25
PH12014502085B1 (en) 2014-11-24
GT201400199A (es) 2018-10-15
US12280106B2 (en) 2025-04-22
KR20220008945A (ko) 2022-01-21
US20190216920A1 (en) 2019-07-18
CN104602706A (zh) 2015-05-06
KR102503316B1 (ko) 2023-02-23
EA030866B1 (ru) 2018-10-31
WO2013142377A2 (en) 2013-09-26
GEP201706650B (en) 2017-03-27
PH12014502085A1 (en) 2014-11-24
WO2013142377A3 (en) 2014-01-23
CR20140432A (es) 2015-01-09
AR090472A1 (es) 2014-11-12
BR112014023398A2 (pt) 2017-07-11
TN2014000393A1 (en) 2015-12-21
EP2827898B1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
Jansen et al. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination
CL2018003769A1 (es) Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
PH12018501047A1 (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
PE20141482A1 (es) Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos
MX2018009917A (es) Vacuna contra el virus del zika.
CO7160021A2 (es) Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares
CO2019011548A2 (es) Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos
AR079767A1 (es) Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
AR110632A1 (es) Vectores del adenovirus canino
AR122653A1 (es) Vectores de hvt recombinantes que expresan hemaglutinina de influenza y composiciones inmunogénicas, su producción y usos
BR112022004488A2 (pt) Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
MX2018015756A (es) Construcciones de virus de la enfermedad de marek recombinantes no patogenicas codificadoras de antigenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad bursal infecciosa.
WO2017044895A3 (en) MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
ECSP14023407A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
PE20190222A1 (es) Virus recombinante de la enfermedad de newcastle que expresa una proteina inmunomoduladora como adyuvante molecular
AR130779A1 (es) Vacunas de combinación
LIU et al. Advances in live attenuated vaccines by targeting host microRNAs
PE20160940A1 (es) Newcastle recombinante expresando las proteinas s del virus de bronquitis aviar y sus aplicaciones
TH141649A (th) รีคอมบิแนนท์เวกเตอร์เฮอร์ปีส์ไวรัสของสัตว์ปีกและวัคซีนสำหรับการก่อภูมิคุ้มกันสปีชีส์ของนกน้ำ
TH148817A (th) รีคอมบิแนนท์ไวรัสเริมของนกชนิดมัลติวาเลนต์และวัคซีนเพื่อสร้างภูมิคุ้มกันสำหรับสปีชีส์ของนก